BioCentury | Oct 28, 2017
Product Development

Chinks in the armor

...Inc. , which led to the development of Phase II idiopathic pulmonary fibrosis (IPF) therapy CC-90001...
...ozanimod, Celgene’s inflammation and immunology portfolio has three candidates in Phase II testing: JNK inhibitor CC-90001...
Items per page:
1 - 1 of 1